Popular Articles

VIA Pharmaceuticals Meets With FDA To Discuss Next Steps For VIA-2291 And Phase 3 Outcome Trial In Cardiovascular Disease
VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, announced today that an end of Phase 2a meeting for the Company"s lead drug, VIA-2291 (atreleuton), was recently held with the U.S. Food and Drug Administration (FDA). The Company reviewed safety and biologic activity data from the VIA-2291 Phase 2 CEA and ACS trials with the FDA and received guidance including suggestions from the Agency on the Company"s Phase 3 trial design. Buy arimidex to treat cancer.

Skills For Catheter Insertion Improved By Simulation Training
New technology allows student doctors to practice operations and other procedures on simulators before trying them out on real patients, just as pilots practice for emergencies on aircraft simulators. Medical educators feel that this will increase patient safety, by avoiding first-time mistakes being made on live patients. But does education by simulation actually work? Can doctors learn new skills on simulators instead of on humans?

generic viagra online


News of the day
Drug That Targets Vasculature Growth Attacks Aggressive Thyroid Cancer
A medication that helps stop the growth of new blood vessels has produced dramatic benefits for some patients with aggressive thyroid cancer, research from Mayo Clinic indicates.
Nutrition

Fluidigm Introduces New TOPAZ(R) Protein Crystallization Chip That Provides A "Screen To Beam" Solution

In the rarified world of protein crystal hunters, Fluidigm"s TOPAZ® system is the tool that has helped researchers solve the structures of proteins from the Ebola Virus and Avian Flu Influenza. Now Fluidigm is introducing its new 1.96 Diffraction Capable (DC) integrated fluidic circuit which will allow researchers something they have long sought - direct screen-to-beam capabilities without the need to physically harvest a crystal from the device. The TOPAZ system has long been recognized for providing the industry"s most efficient screening method -- Free Interface Diffusion (FID). The system samples crystallization space more broadly while using significantly less protein sample than any other products on the market. It therefore finds protein crystals more efficiently than any other offering. These microscopic crystals can hold the key to understanding and possibly preventing diseases of catastrophic proportions, such as influenza epidemics. Fluidigm"s new TOPAZ 1.96 DC chip provides the ability to obtain high quality in situ, diffraction data, thus allowing true "hands off" diffraction-based screening. "The TOPAZ 1.96 DC chip gives researchers the ability to screen broadly to find protein crystals and then immediately expose their targets to an x-ray directly through the chip," noted Gajus Worthington, Fluidigm president and chief executive officer. "The 1.96 DC chip finally allows screening decisions to be based on data rather than guesswork." "We have been using Fluidigm"s 1.96 DC chip for several months. Its ability to allow diffraction-based screening has been a tremendous benefit to our research," said James Berger, Professor of Biochemistry and Molecular Biology, Department of Molecular and Cell Biology at the University of California, Berkeley. "The TOPAZ 1.96 DC chip is a game-changer that has allowed us to solve structures much more quickly than before because we can immediately concentrate our efforts on crystals that provide the highest quality diffraction data from the outset." Diffraction-based screening is made possible because the Fluidigm 1.96 DC chip uses advanced chip design techniques. The chip materials and dimensions have been chosen to optimize its performance for in situ diffraction, allowing the entire chip to be placed directly in the path of an X-ray beam. If necessary, "cut-outs" of the chip can be made to fit onto pins, which can be cryopreserved and placed onto standard goniometer heads for data collection. The Fluidigm 1.96 DC chip is the newest addition to the company"s TOPAZ System which consists of chips, hardware and software that simplify and automate nanoscale free interface diffusion. Fluidigm


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):